Introduction: Allergic rhinitis (AR) is one of the most common chronic respiratory diseases observed in the pediatric population, producing a significant morbidity, and an economic burden due to direct medical costs and indirect costs. Despite the high prevalence of AR in children and the importance of the use of topical intranasal corticosteroids for its treatment, comparative analyses of alternative treatments in pediatric patients, in terms of both cost and effectiveness are lacking. Methods: A decision-analysis model was developed to estimate the cost-effectiveness of mometasone furoate nasal spray (MFNS) compared to beclomethasone dipropionate nasal spray (BDNS) for treating pediatric patients with AR over a 12-month period. Effectiveness parameters were obtained from a published study in which authors performed a systematic review of the literature. Cost data were obtained from a hospitaĺs bills and from the national manual of drug prices. The study assumed the perspective of the national healthcare in Colombia. The outcomes were three effectiveness measures summarized in a therapeutic index (TIX).
INTRODUCTION
Allergic rhinitis (AR) is a global health problem and one of the most common chronic respiratory diseases observed in the pediatric and adult population, with an estimated prevalence of approximately 20-40 million in the US population [1] . In Colombia a prevalence of AR symptoms has been reported ranging from 29.5% to 33.9% for the whole population, and from 25.9% to 53.8% for the pediatric population [2, 3] . Despite the fact that AR is not directly associated with a high rate of mortality or a high rate of hospitalization, the disease produces a significant morbidity. This condition has a major impact on the quality of life, sleeping habits, academic performance, daily activities, and concentration of sufferers [4] . Furthermore, in pediatric patients, improperly managed AR may contribute to the worsening of comorbid conditions, including asthma, rhino sinusitis, and otitis media [5] . The aforementioned factors lead to significant economic burden due to direct medical costs such as prescriptions and ambulatory care visits, and indirect costs such as absenteeism from school and work [6, 7] .
Although there are many therapeutic options for the treatment of AR, topical intranasal corticosteroids (INS) are considered the most effective medication class for controlling symptoms of the disease [1] . INS have shown to reduce nasal congestion, rhinorrhea, sneezing, pruritus, and can also relieve ocular symptoms [8] . In Colombia, beclomethasone dipropionate nasal spray (BDNS) and mometasone furoate nasal spray (MFNS) are the two most commonly prescribed and the leading INS by market share in the country [9] ; however, currently BDNS is the only INS included in Colombia's compulsory health insurance plan.
Despite the high prevalence of AR in children and the importance of the use of INS for the treatment of AR, comparative analyses of alternative treatments in pediatric patients, in terms of both cost and effectiveness are lacking.
These comparative analyses are important because differences in cost of acquisition, efficacy, side effects, and therapeutic adherence between alternative treatments for AR could have a considerable impact on the control and in the tremendous economic burden of the disease. Cost-effectiveness analysis (CEA) provides a tool with which to incorporate both cost and effectiveness of alternative treatments.
The aim of the present study was to compare the cost-effectiveness of MFNS compared to BDNS for treating pediatric patients with AR in Colombia. to continue treatment with a more effective INS or to send the patient for additional diagnostic and therapeutic procedures (Fig. 1) . The model assumed that there would be complete compliance with either treatment measure throughout the entire year of follow-up.
METHODS

Structure of the Model
Although as determined by the natural history of AR it could be more appropriate to use a Markov model instead of a simple decision tree, we used the latter because we considered that using a simple decision tree it was possible to include the most important clinical events resulting from each of the two therapeutic options without unrealistic simplifying assumptions.
The model compared the one-year direct medical costs (including medical consultations, imagenology studies, and other diagnostic and therapeutic procedures for patients with no improvement of symptoms on therapy with INS, or for patients who presented treatment- Fig. 1 Diagram of cost-effectiveness model for each treatment option. Asterisk For patients whose symptoms do not improve and the decision is to continue treatment with a more effective topical intranasal corticosteroid, the model follows as it is depicted for beclomethasone dipropionate nasal spray related adverse events such as epistaxis or increased intraocular pressure) and disease outcomes from the perspective of the national healthcare system in Colombia.
Three effectiveness measures were chosen as the basis for this model: a composite total nasal symptom score (TNSS), defined as the average effect size for each of the two comparators for nasal symptoms, a composite total ocular symptom score (TOSS), defined as the average size for ocular symptoms, and a patient (or physician) global assessment (PGA).
Sources of Data
Disease Outcomes and Clinical Parameters
Assumptions regarding the probability of improvement of nasal symptoms, ocular symptoms and global assessment, the probability of treatment-related adverse events, and if these adverse events comprised epistaxis or not, were derived from the literature.
Specifically, we identified a published study in which authors performed a systematic review of the literature (1966 to June 2009) to identify potentially relevant studies on efficacy and safety of several INS, including BDNS and MFNS [10] . In this study, the authors aimed to develop a therapeutic index (TIX) reflecting both efficacy and safety of these substances in a combined assessment. To develop this TIX, the authors performed meta-analyses for each single INS and for the parameters TNSS, TOSS, PGA, and epistaxis. The meta-analyses results for the different INS and the parameter TNSS, TOSS, PGA, and epistaxis were ordered and then categorized into scores from 0 to 3 using quartiles. The scores of long-term side effects and systemic ocular side effects were based on the highest level of evidence reflected by the study type of available studies and its results. The score points for the three efficacies and the three safety parameters were then summarized for each INS resulting in individual summation scores of 'sum efficacy' (ES) and 'sum side effects' (AES), which could range between a minimum of 0 and maximum of 9 points. A high ES would indicate a high efficacy and a high AES a high potential for side effects. The final TIX score was then calculated as the ratio of ES and AES with a theoretical maximum of 9 points indicating an optimal balance of a maximum efficacy and a minor potential of side effects [10] . Table 1 presents the summation scores of each parameter as well as the final TIX score for BDNS, MFNS, and for budesonide aqueous nasal spray (BANS). We included the data of BANS because, for patients whose symptoms do not improve, the model incorporates the possibility (decision node) to continue treatment with a more effective INS. Based on the summation scores of ES, the model assumed that MFNS is the next most effective Table 1) . Probabilities of efficacy parameters were obtained based on the efficacy scores summarized in the TIX. The probability of improvement of symptoms with each one of the INS was calculated as the proportion of the maximum score for efficacy parameters with respect to the maximum possible score for efficacy parameters, and the probability of side effects with each one of the INS was calculated as the proportion of the maximum score for side effects parameters with respect to the maximum possible score for side effects parameters. Likewise, probabilities of efficacy parameters for TNSS, TOSS, and PGA were calculated as the proportion of the TIX scores for each parameter with respect to the maximum score for efficacy parameters, and probability of epistaxis was calculated as the proportion of the TIX score for epistaxis with respect to the maximum score for side effects.
Resource Utilization and Costs
As mentioned, the CEA was conducted from the perspective of the national healthcare system in Colombia and hence only direct costs were included in the analysis. Carlo simulation was conducted to account for the uncertainties associated with the model parameters using a cohort of 10,000 trial simulations for both alternatives. This probabilistic sensitivity analysis allowed us to generate 95% uncertainty intervals (UI) around costs and effects. These were presented graphically on a cost-effectiveness plane to show the estimated joint distribution of incremental costs against incremental effects and evaluated using net benefit analysis [15] . Subsequently, a cost-effectiveness acceptability curve (CEAC) was derived from these data [16] to identify which alternative would be the most cost-effective at various thresholds of willingness-to-pay (WTP) for TIX score point. All analyses were performed with software (TreeAgePro 2012, TreeAge Software,
Williamstown, MA, USA).
RESULTS
Base-Case Analysis
With respect to single INS the value of both the unit cost and the cost of daily treatment with BDNS were lower than those costs of MFNS, whereas the efficacy of MFNS was greater than the efficacy of BDNS. Likewise, the potential for side effects was higher for BDNS compared to MFNS ( Table 2) .
While the anterior nasal packing was the resource with the greatest unit cost for patients with drug-related adverse events with INS use, septoplasty was the resource with the greatest unit cost for patients whose symptoms did not improve with the use of INS (Table 3) . Likewise, while cauterization was the resource with the greatest rate of utilization for patients with drug-related adverse events with INS, immunotherapy, and endoscopic nasopharyngoscopy were the resources with the greatest rate of utilization for patients whose symptoms did not improve with the use of INS (Table 4 ).
Using the base-case assumptions, the model showed that compared to BDNS, therapy with MFNS was associated with lower costs (US$229.78 vs. US$289.74 average cost per patient over 12 months) and a greater improvement in TIX score (0.9724 vs. 0.8712 score points on average per patient over 12 months), thus leading to dominance. A position of dominance negates the need to calculate an incremental cost-effectiveness ratio ( Table 5 ).
Sensitivity Analyses
One-way, two-way, and multi-way deterministic sensitivity analyses (using a tornado diagram) showed that the cost of pediatric consultation and the cost of MFNS have the highest impact on the model outcome.
However, MFNS was the dominant strategy over all the ranges of the cost of pediatric consultations and the cost of MFNS analyzed. Probability calculations based on three efficacy and three safety parameters summarized in a therapeutic index [10] Parameter distributions used in the probabilistic sensitivity analysis are presented in The CEAC shows that the probability that daily therapy provides a cost-effective use of resources compared to intermittent therapy exceeds 99% for all WTP thresholds (Fig. 3) .
DISCUSSION
The present study shows that compared to BDNS, therapy with MFNS for treating pediatric patients with AR is a dominant strategy because it showed a greater improvement in a TIX reflecting both efficacy and safety, at lower total treatment costs.
Although the variables that exhibited a significant effect on these results were the cost of pediatric consultation and the cost of MFNS, therapy with MFNS was the dominant strategy over all the ranges of the cost of pediatric consultations and the cost of MFNS analyzed. It is worth mentioning that, to the best of our knowledge, this is the first study to compare MFNS and BDNS for treating pediatric patients with AR, in terms of both cost and effectiveness.
The findings of the present study support the use of MFNS as the most efficient therapy in pediatric patients with AR diagnosis in Colombia and probably in other similar lowand middle-income countries (LMIC), at least when it is compared exclusively with BDNS. These results are important because although MFNS has a higher cost of acquisition relative to BDNS, it is associated with lower total treatment costs and better health outcomes in pediatric patients with AR. These findings should help to support the daily clinical decision-making process of choosing between a range of options for these patients. When choosing the most efficient therapy for treating pediatric AR, it is possible to impact on the significant morbidity and economic burden associated with the disease. Although traditionally it has been assumed that safety and efficacy is proven for all available INS, and that they are all equally effective in controlling symptoms of AR, our results do not support this previous assumption. Although there is no single trial which directly compares all the available INS, and our model did not include all INS currently licensed in Colombia for use in children with AR, the systematic aggregation and analysis of both efficacy and cost data in our study suggests that the choice among the different treatments available can have a great impact on the health outcomes and costs of the disease.
Our results agree with those published by Portnoy et al. [17] who found, using an evidence-based medicine approach to assess efficacy and safety in a combined parameter Likewise, in agreement with our findings, there are reports that support the difference in the proportion of costs for a daily dose of BDNS [21] . Third, although we assumed that differences in the results of the efficacy and safety parameters summarized in the TIX have a similar clinical significance, it's unclear whether this assumption is actually true. This is mainly because there has not been a direct comparison of all INS with regard to the efficacy and safety outcomes analyzed in the present study. Fourth, assumptions regarding the probability of improvement of nasal symptoms, ocular symptoms and global assessment, the probability of treatmentrelated adverse events, and if these adverse events comprised epistaxis or not, were derived from a published study in which authors only included studies up to 2009, so it is probable that this study does not reflect the current state of scientific knowledge. However, in this study, authors performed a systematic review of the literature and developed a TIX reflecting both efficacy and safety of these substances in a combined assessment.
Although this fact increase the confidence in obtaining unbiased results, it would be important that future studies determine the cost-effectiveness of different INS based on more recent literature. Finally, cost data were obtained from a single clinical center and may not be representative of the whole country. However, these data were obtained from a pediatric clinic that receives patients from the most important and representative medical insurance companies in the city. Moreover, costs were subject to wide sensitivity analyses.
CONCLUSIONS
The present analysis shows that in Colombia, compared with BDNS, therapy with MFNS for treating pediatric patients with AR is a dominant strategy because it showed a greater improvement in a TIX reflecting both efficacy and safety, at lower total treatment costs.
Although it is difficult to assess the clinical relevance of differences in efficacy and safety parameters summarized in the TIX, these results may help to support clinical decision making until more robust evidence is available.
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